Is camrelizumab associated with a higher risk of disease progression compared to pembrolizumab?
The question asks whether camrelizumab, a PD-1 inhibitor, carries a higher risk of disease progression compared to pembrolizumab in advanced non-small cell lung cancer (NSCLC). A real-world retrospective study directly compared these drugs and found that for nonsquamous NSCLC, camrelizumab was associated with a higher risk of progression and death when used as second-line or later therapy. However, this finding comes from a single study, and no direct head-to-head trials were available. Other sources in this set focus on pembrolizumab's benefits or different drug combinations, so the evidence is limited.
What the research says
A real-world retrospective study of 409 patients with advanced NSCLC compared four PD-1 inhibitors, including camrelizumab and pembrolizumab 79. For nonsquamous NSCLC, camrelizumab given as second or later-line treatment was associated with a higher risk of disease progression (hazard ratio [HR] 2.29; 95% CI 1.01-5.19) and death (HR 3.14; 95% CI 1.28-7.74) compared to pembrolizumab 79. However, objective response rates were similar between the drugs, and no significant differences were seen in squamous NSCLC 79. Other sources in this set do not directly compare camrelizumab and pembrolizumab. Instead, they show that pembrolizumab improves survival versus chemotherapy in advanced NSCLC with high PD-L1 expression 25, and that combination therapies like domvanalimab plus zimberelimab may improve progression-free survival 4. A network meta-analysis of anti-PD-1/PD-L1 regimens in nonsquamous NSCLC did not include camrelizumab but ranked pembrolizumab plus chemotherapy among the best for overall survival 6. The camrelizumab finding is from a single retrospective study, so it should be interpreted cautiously.
What to ask your doctor
- Given my NSCLC subtype (squamous vs. nonsquamous), what is the evidence for camrelizumab versus pembrolizumab?
- If I am considering second-line or later treatment, does the higher progression risk with camrelizumab apply to my situation?
- Are there any ongoing or completed head-to-head trials comparing camrelizumab and pembrolizumab that might guide my choice?
- How do my PD-L1 expression level and overall health affect which PD-1 inhibitor might be best for me?
- What are the potential side effects of camrelizumab compared to pembrolizumab, and how are they managed?
This question is drawn from common patient questions about Oncology and answered using cited medical research. We do not provide individualized advice.